ZHIFEI-BIOL(SZ:300122) Xin Lang Cai Jing·2026-01-16 02:45Core Viewpoint - The stock of Zhifei Biological experienced a decline, with a current price of 19.03 yuan per share and a market capitalization of 45.554 billion yuan, reflecting a challenging financial performance in recent periods [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a significant year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion yuan, marking a year-on-year decline of 156.10% [2]. - The company has cumulatively distributed dividends of 7.318 billion yuan since its A-share listing, with 3.194 billion yuan distributed over the past three years [3]. Shareholder and Market Activity - As of December 19, 2025, the number of shareholders for Zhifei Biological was 124,500, a decrease of 2.69% from the previous period, while the average circulating shares per person increased by 2.76% to 11,358 shares [2]. - The stock experienced a net outflow of main funds amounting to 25.6679 million yuan, with significant selling pressure observed in large orders [1]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is primarily engaged in the research, production, and sales of vaccines and biological products. Its revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. - The company operates within the pharmaceutical and biological industry, specifically in the vaccine sector, and is associated with concepts such as hepatitis treatment, vaccines, anti-influenza, biomedicine, and innovative drugs [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders included Hong Kong Central Clearing Limited, holding 33.5608 million shares, and several ETFs, all of which saw a reduction in their holdings compared to the previous period [3].